In patients with high PD-L1 expression identified before surgery, clinicians should consider the possibility of lymph node metastasis when determining surgical strategy, including the extent of lymph ...
Impact of body mass index (BMI) on survival outcomes in patients with cancer treated with immune checkpoint inhibitors (ICPI): A systematic review and meta analysis. This is an ASCO Meeting Abstract ...
Utilizing a >400 RFU threshold, treatment with leronlimab was associated with the upregulation of PD-L1 in CTCs and cancer-associated macrophage-like cells (CAMLs) in 76% (n=16/21) of patients overall ...
Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...
Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...
Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a ...
Researchers demonstrated that newly developed molecules designed to block an immune checkpoint can trigger a powerful immune response against tumors. Scientists at MIT and Stanford University have ...
Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells ...
Accurately determining the binding sites in protein-protein interactions is essential for breakthroughs in biomedicine. However, existing experimental methods are slow and expensive. Computational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback